List of Therapeutic Companies in United Kingdom - 264

199 Biotechnologies is an early-stage
company developing first-in-class therapies that target the fundamental mechanisms of aging, with the goal of transforming the landscape of age-related disease treatment and prevention.

Accession Therapeutics Limited is based in Oxford, UK. Its platform technology, TROCEPT, is delivering a proprietary internal pipeline for Accession Therapeutics with significant innovation opportunities available for partnering. Products from the platform are expected to have strong clinical and commercial potential, convenient intravenous administration for better patient access and compliance, and a competitive cost of goods sold via an established manufacturing route. The potential of TROCEPT is illustrated in the animation here. Accession Therapeutics has raised >$66m to date backed by high net worth individuals, iGlobe Partners, Primavera Venture Partners, Birk Venture and other international biotech investors.

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA. We are a highly experienced team with a long-standing track record of entrepreneurial and investment success through turning break-through science into approved medicines or medical products. We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach. Our investments are focussed in new drug discovery - small molecules, biologics and new modalities - med tech, enabling technologies and vaccines. As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well connected team to support each investment. We work in close alignment with our management teams, and partner with them to realise their vision - achieving superior financial returns by bringing innovation to patients. The companies in which we have invested since the year 2000 have discovered and developed, fourteen approved medicines and products - to the benefit of patients, physicians and our investors.

Aelius Biotech is a UK-based biotechnology company founded in 2018, located in Newcastle upon Tyne. The company specializes in developing in vitro gastrointestinal models, which simulate the digestive process. This innovative model includes cell-compatible mucus, allowing for a comprehensive understanding of digestion and absorption. Aelius Biotech offers contract research services focused on animal-free testing for pharmaceuticals, consumer health products, and functional foods. They have collaborated with notable clients, including Huel, and have attracted interest from the alternative protein and lab-grown meat sectors. The company has experienced significant growth, expanding its workforce and revenue following successful funding rounds in 2023 and 2025.

Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by its lead clinical-stage program, NG-350A, which is being investigated in an ongoing Phase 1 clinical study in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

AKL Therapeutics is a pharmaceutical company changing the way drugs are developed by seeking inspiration from nature to combat some of the biggest challenges facing modern medicine today. We are committed to transforming patient’s lives through pioneering innovation. We begin by identifying secondary metabolites of plant origin, with proven efficacy and safety. These metabolites are then synthesized before undergoing standard pharmaceutical clinical development. This innovative approach greatly increases the chances of success, while reducing the risk of side effects. Formal human clinical trials are currently underway assessing the safety and efficacy of an investigational oral therapy, ‘APPA’ in the treatment of osteoarthritis, a common and devastating disease with limited treatment options and no cure. APPA is also being evaluated in other inflammatory diseases and other molecules are also under investigation. AKL Research & Development Ltd, trading as AKL Therapeutics Ltd, welcomes enquiries from potential investors and partners as we continue the development and commercialisation process.

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Allergy Therapeutics is a visionary immunology business with specialist experience in the research and development of allergy treatments. We have a well-established commercial presence in Europe and are focused on the US market. We specialise in the diagnosis and treatment of allergy. We mainly sell our products in European countries and our pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, as well as a peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside of allergy are also under evaluation.

At Alliance Pharma plc (AIM: APH) we are a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world. We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. We have previously enhanced our organic growth through selective, complementary acquisitions. Headquartered in Chippenham, UK, we employ around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. Over the last year, Alliance has sharpened its purpose, vision and strategy to align with the stated move towards a predominantly consumer healthcare company, to better position the company for the future, and in response to changing underlying market dynamics. In line with this new strategy, Alliance will focus on the global priority categories of helping damaged skin and supporting healthy aging. Our vision is to be a high performing consumer healthcare company, built on a portfolio of leading, trusted and proven brands. Consumer health products currently deliver 75% of our revenue sales and this continues to be an area of focus going forward. For more information, please visit our website: www.alliancepharmaceuticals.com Adverse Event Reporting Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Pharmacovigilance at Alliance Pharmaceuticals (tel: 01249 466966, email: pharmacovigilance@alliancepharma.co.uk)

AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC). The GTC was founded in 2001 to catalyse the application of pioneering research to gene therapy development and manufacturing related to cystic fibrosis and other respiratory diseases, and originated at Imperial College London and the Universities of Oxford and Edinburgh. AlveoGene has secured an exclusive licence to a proprietary and validated next-generation lentiviral delivery platform developed by the GTC for the treatment of respiratory diseases with high unmet need (excluding the use of the CFTR gene which is mutated in cystic fibrosis). Gene therapies developed using our “InGenuiTy™” platform can be delivered through a nebuliser, transducing lung epithelial cells with high efficiency and producing a long duration of action, and can achieve these effects following repeated administration. The platform has been developed over more than a decade, supported by approximately £72 million in grant funding, including from the Wellcome Trust, Department of Health and Social Care, Medical Research Council and the Cystic Fibrosis Trust.

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally restore normal physiological function in women suffering with mixed urinary incontinence. The company's first therapy, Amber UI, is an intelligent closed-loop bioelectrical therapy for urge and mixed urinary incontinence. The startup has also acquired Bioinduction, a fellow U.K.-based company and the maker of the Picostim DyNeuMo platform.

At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches, addressing limitations associated with the use of a narrow range of protein degrading mechanisms. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

AMPLY Discovery is a Belfast-based techbio company that deploys machine learning and synthetic biology to mine vast biological data to discover novel drug and nutraceutical candidates. Their technology digitizes life's diversity, using next-gen sequencing for drug discovery to tackle complex diseases such as cancer, metabolic disease, and infectious diseases through AI (artificial intelligence). They have raised over €1.6 million in grant funding from Innovate UK to develop their drug discovery platform.

Amytrx Therapeutics is advancing a new class of peptide therapies to overcome inflammatory diseases—with a vision of providing transformative medicines to patients. Drawing on 25 years of research, Amytrx is harnessing the power of novel anti-inflammatory peptide discoveries to advance new medicines aimed at the prevention and treatment of inflammatory diseases. Our lead therapeutic candidate, AMTX-100, is bioengineered from human protein sequences that modulate the immune system by a natural process, reducing pathogenesis in a range of chronic diseases mediated by excessive inflammation. Joining forces with institutions for clinical research, Amytrx Therapeutics is dedicated to transforming the conventional treatment of chronic inflammatory diseases using biological technology that is easily understood by the human body in a way that is safe, effective, and simple to use.

Antikor is a privately-held biotechnology company originally spun-out from Imperial College. We specialise in the discovery and development of small-format Antibody (Fragment) Drug Conjugates, known as FDCs. FDCs are a form of targeted cytotoxic chemotherapy combining the specificity of antibodies with the potency of small-molecule chemotherapy drugs. Specifically, FDCs are smaller than conventional Antibody Drug Conjugates (ADCs) meaning better tumour penetration and more rapid systemic clearance, potentially leading to a higher clinical therapeutic index. Antikor are developing the next-generation of solid tumour therapies, with a major interest in gastro-intestinal cancers.

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners. Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. For more information, please visit our website at www.apollotherapeutics.com

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

At Argent BioPharma, we are committed to pioneering the future of healthcare. Our approach is rooted in a profound understanding that advancing medical science is not just about treating diseases but pre-empting and redefining how they are managed. This philosophy guides our R&D efforts, where we focus on the intricate science of the immune system and the exploration of advanced technologies. As we progress on this ambitious path, we invite you to follow our journey and be a part of a transformative shift in healthcare. At Argent BioPharma, we're not just changing treatments; we're changing lives.

Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor ART6043, as monotherapy and combination treatments. Together with our strategic partnerships with Merck KGaA and Novartis, and research collaborations with premiere institutions like Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute we are pioneering validated approaches to DDR drug discovery. Visit our website at https://www.artios.com/ for more information. Artios is based at the Babraham Campus in Cambridge, UK. If you are interested in working at Artios and have the qualities to be part of our team, please submit your application via our website. We are also very mindful of scams that involve recruitment. At this time please note we are currently not working with any third parties in India for recruitment.

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

Since 1987, Astrea Bioseparations has been pioneering the design, development and manufacture of affinity purification technology for lab-scale and industrial-scale bioprocessing. With over 25 years experience and success in the development of affinity products and design of new custom adsorbents, Astrea is a world leader in its field. Astrea Bioseparations has sales and support offices in North America and Europe, R&D facilities in Cambridge, UK and manufacturing facilities located on the Isle of Man, British Isles and Joliette, QC, Canada ensuring that we are able to meet your needs and support your application wherever you are. OUR EXPERTISE: • Extensive range of bioseparation products • Custom designed chromatography adsorbents • Over 25 years experience & success • Cost effective solutions • Proven Mimetic Ligand™ technology • Dedicated professional service • Full technical support & in-house training • Experts in adsorbent development & downstream process optimization • Established manufacturing facility (ISO 9001)

aTen Therapeutics is an innovative biotechnology company developing novel therapeutic antibodies to target a fundamental control pathway associated with cancer and several other major diseases. Their technology is focused on antibody discovery and cutting-edge technology development.

Charnwood Discovery is part of Concept Life Sciences following an acquisition in November 2024.

Aurum Biosciences is developing novel therapeutics and diagnostics in areas of unmet clinical need. The initial indication for Aurum's ABL-101 injectable is for the treatment of acute ischemic stroke. The company is focused on developing oxygen carriers for use as therapeutics and diagnostics.

Autifony Therapeutics Limited (“Autifony”) is a clinical stage biotechnology company dedicated to developing new medicines to treat rare genetic CNS disorders by deploying its pioneering ion channel drug discovery platform.

Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.

Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms. The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families. Avacta’s proprietary pre|CISIONᵀᴹ targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONᵀᴹ drug candidate, AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic by the second half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a Biosynthetic Wound Matrix, in the United States.

Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.

Barinthus Biotherapeutics plc (formerly Vaccitech plc), a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company’s prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing a COVID-19 vaccine with the University of Oxford, which is approved for use in various territories and licensed worldwide to AstraZeneca through Oxford University Innovation. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.

Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field.

Bastion Therapeutics is a preclinical stage biotechnology company with a mission to develop novel Treg therapies to address the unmet clinical need for inflammatory disorders. We leverage our proprietary GRIT™ platform technology to enhance Tregs to modulate the immune system and overcome challenges associated with previous generations of Treg therapies. Our vision is to provide life-changing therapies that are efficacious, durable and safe to patients suffering from inflammatory disorders.

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

BioCorteX is a biotechnology company that utilizes artificial intelligence and computational modeling to enhance therapeutic development, particularly in the area of microbiome-host interactions. The company operates through two entities: Biocortex Ltd, established in the UK in 2021, and BIOCORTEX, INC., which opened in 2023. BioCorteX specializes in AI-driven platforms that aim to reduce risks in drug development and improve clinical trial outcomes. The company offers several core services, including in silico clinical trials that simulate drug-bacteria-host interactions to predict clinical outcomes, microbiome analysis to assess how bacterial diversity affects drug efficacy, and therapeutic development support for various sectors such as pharmaceuticals and cosmetics. Their proprietary foundational emulator integrates microbiome data with AI to simulate human physiological responses to drugs, while their drug interaction models test numerous medications to identify success factors, particularly in antibody-drug conjugates for cancer therapy. BioCorteX targets pharmaceutical companies, biotech firms, and the cosmetics industry, providing insights to optimize product performance and safety.

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.

Bio Products Laboratory Limited (BPL) is headquartered in Elstree, near London (UK). BPL's mission is to provide a continuous supply of high quality plasma derived products to a growing global market, through investing in the latest research, technology and manufacturing methods, and by ensuring on-going and responsive support to health professionals throughout the world. We are committed to research and development to maintain a key position in a constantly changing market in the 21st century. BPL manufactures a wide range of products from blood plasma. These products fall broadly into three main groups: • Human Albumin Solutions • Human Immunoglobulins • Human Coagulation Factors

Biosceptre is developing a multi-targeted universal CAR-T system, designed to incorporate our nfP2X7 technology, to be capable of treating a range of cancers.

Biotherapy Services Ltd. (BTS) is a pharmaceutical biotechnology company developing and delivering novel autologous therapies for complex and chronic wounds 🥽 🥼. Biotherapy Services, composed of clinicians, technicians, and healthcare managers, was created to bring the most effective platelet-enriching technology to medical practices in the UK and Eire 👩‍🔬 👨‍⚕️. The company has developed proprietary expertise and a unique GMP standard operational service model to provide the RAPID™ Biodynamic Haematogel autologous wound care treatment, targeting complex and chronic wounds such as Diabetic Foot Ulcers and Pressure Sores 🦵️ 🦶️. The RAPID™ Gel harnesses the patient’s own platelets to speed healing, growth, repair, and recovery 🧬️. BTS is currently conducting the RAPID-1 Trial to investigate the efficacy of RAPID™ Gel in wound closure compared to usual and customary care 🔎.

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio's trademarks, visit www.bit.bio/trademarks

BiVictriX is an emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer. Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues. Thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of the major factors limiting the development of this otherwise promising therapeutic class. BiVictriX's Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links the Company's in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications. The Company's initial focus is on the generation of Bi-Cygni Antibody Drug Conjugates (ADCs), with future plans to expand the technology to other therapeutic modalities (Cell engagers and CAR-T).

Bloomsbury Genetic Therapies ("Bloomsbury") is a clinical-stage biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies. The Company was spun out of University College London and launched in October 2022 with funding from UCL Technology Fund. Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs.

Blue Earth Therapeutics Ltd is a clinical stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat patients who have cancer. With proven leadership and therapeutic radiopharmaceutical expertise, Blue Earth Therapeutics has an emerging pipeline of precision targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer with plans to expand into additional disease areas in oncology. The Blue Earth Therapeutics story begins in 2021, when the company was formed in Oxford, UK as a sister company to Blue Earth Diagnostics Ltd and part of the Bracco family of companies. Bracco Imaging S.p.A. is a world‐leading diagnostic imaging provider, headquartered in Italy. The Blue Earth Therapeutics team strongly believes in the potential of targeted therapeutic radiopharmaceuticals and is committed to bringing these innovative technologies to clinicians and patients worldwide.

Britannia Pharmaceuticals, part of the STADA Arzneimittel AG group of companies, is a UK based pharmaceutical company specialising in the neurology market. Britannia focuses on innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson’s disease. We are highly committed to improving the quality of life for People with Parkinson's disease.

Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developing novel therapeutics targeting free fatty acid receptors for NASH, Type 2 Diabetes (T2D) and other potential indications. Caldan has arisen from a long-term collaboration between Professor Trond Ulven at the University of Southern Denmark and Professor Graeme Milligan of the University of Glasgow.

CardiaTec is a TechBio company employing computational methods to decode the biology behind cardiovascular disease. We leverage large and high-dimensional human omics data to better navigate complex disease biology to discover novel and differentiated therapeutics.

Maintaining musculoskeletal health is the keystone of overall health as we get older. As we age our physical condition gradually deteriorates, leading to loss of strength, fitness and mobility. In most cases, this isn’t due to a simple decision to stop exercising. It is due to the breakdown of musculoskeletal function caused by disease. Musculoskeletal diseases such as osteoarthritis, tendinopathy and lower back pain are the primary causes of disability and early retirement in people over the age of 65. Currently, there are no approved disease-modifying drugs for these diseases, meaning that physical decline in old age is inevitable. At Causeway, we believe that physical decline in old age is not inevitable and in indeed may be reversible. To address this, we are developing a range of therapies that treat common MSK diseases that will allow us to remain fit and active into our nineties and beyond. Staying active as we get older also reduces the risk of developing osteoporosis, dementia, diabetes, obesity, cancer and cardiovascular disease.

Synthetic biology is changing the way we think about diagnosing and treating microbiome-based diseases. At CC Bio, we harness the power of synthetic biology to engineer and edit the microbiome with surgical precision. Our goal is to eliminate microbiome-based disease in a potent, specific and prophylactic fashion, harmonising the relationship between eukaryotic and microbial cells. By considering the lifestyle needs of our patients, and understanding each microbiome-based disease holistically, we are elevating this fundamental aspect of human health out of the antibiotic era, putting power back in the hands of the consumer.

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of cannabis-based products, initially for the chronic pain market.

Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.

Cellesce Ltd is a biotechnology company based in Cardiff, Wales, that focuses on organoid research and bioprocessing technologies. Established in 2013, the company specializes in patient-derived organoids (PDOs) for cancer research, utilizing patented bioprocessing technology to standardize and scale organoid production. The company offers several core services, including the development and manufacturing of standardized cancer organoids for large-scale applications such as compound screening and high-throughput drug discovery. Cellesce also provides scale-up solutions to ensure reproducible organoid batches, meeting the needs of pharmaceutical testing. Additionally, it supports drug discovery pipelines with customized organoid models, particularly in oncology. In December 2022, Cellesce was acquired by Molecular Devices, enhancing its capabilities in integrating organoid technology into drug discovery platforms. The company reported $7.8 million in annual revenue for 2024 and operates with a small team, emphasizing its commitment to advancing organoid-based precision medicine.

Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity"​ in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company’s preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.

CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham. CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific therapeutics to the gut. CHAIN’s Clostridium Assisted Drug Delivery (CADD™) delivery platform is highly differentiated and supports a therapeutic product pipeline for a wide range of clinical indications including localised infection, inflammation and CNS signalling. Our lead asset is an engineered strain that secretes a novel and potent anti-inflammatory molecule targeting Inflammatory Bowel Disease, a chronic gut disease affecting millions worldwide.

CHARM Therapeutics is discovering and developing small molecule medicines against difficult-to-drug targets with our proprietary 3D deep learning-enabled platform, DragonFold. Powered by the first high throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM seeks to deliver innovative approaches to create life-changing therapies for patients.

By mining the genome using our bioinformatics platform we discover and re-purpose natural gene regulatory elements, creating customised gene expression systems to: 1. Improve human health: Creating highly selective and controllable promoters and gene expression cassettes for novel gene and cell therapy systems. Improving the efficiency of biologics production by increasing protein yields in upstream manufacturing processes. 2. Engineer biology: Harnessing synthetic biology to make promoters for a wide array of chassis organisms used in Industrial Biotech. Creating switches and gene circuits that can be employed in the metabolic engineering applications. 3. Enable traits discovery: Designing tissue-selective plant synthetic promoters active across different crop species for Agricultural Biotech applications. Using plant genomics to facilitate the design of environmentally-regulated and pathogen-responsive promoters.

Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system. What we do: Chronos is an Oxford-based biotechnology company operating a semi-virtual R&D model to develop a portfolio of therapies in degenerative and behavioral brain diseases. The team utilises a network of industry- leading contract research organisations to develop NCEs and repurpose existing launched drugs. Chronos also has a dedicated laboratory in Oxford which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen™. Our Focus: - Acquisition, discovery and development of novel proprietary lead candidates. - Repositioning FDA/EMA approved drugs. Targets: - ALS (Lou Gehrig’s Disease) - Other Neurological Diseases - Fatigue - Addictive Behaviour

Coding Bio unites a high throughput wet lab and ML platform to screen, build, and deliver fully-assembled modular therapies like CARs and BiTEs in only months.

Making Medicines More Manageable At Colonis, we repurpose medicines to make them more manageable for patients. By identifying and understanding how unmet clinical needs impact patients, we develop innovative solutions that improve compliance and enhance health outcomes, empowering individuals to live their lives to the fullest. Our mission is to support patients in receiving the most appropriate and accessible treatment for a better quality of life.

We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first clinical development programme is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. We want to transform the patient experience in mental health care.

Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.

With the power to skillfully write meaningful DNA sequences, we embark on a new era where precise control over biology and the manipulation of matter in our environment is possible. Constructive Biology is a spin out from the laboratory of Prof. Jason Chin at the MRC Laboratory of Molecular Biology in Cambridge. Our platform allow us to fundamentally reprogram the genetic code, and make molecules that nature could not make before. We will use our technologies to biosynthesize new classes of enzymes, pharmaceuticals and biomaterials. If you would like to join our team, get in touch!

As a leader in orthopaedic innovation, Corin has pioneered a number of landmark developments since its foundation and is proud to have been able to improve the quality of life of thousands of patients around the world through these groundbreaking products. The company's talented and dedicated teams share a common commitment to deliver quality orthopaedic products and services to patients, surgeons and healthcare providers which exceed expectations and positively impact lives. With an increasingly active and demanding patient population, the need to provide state of the art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin's product portfolio is designed to provide each patient with the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance.

Corryn Biotechnologies is developing a technology to fabricate and deposit biomimetic nano- and micro-fibrous wound dressings directly upon wound sites at the point of care. This technology aims to significantly reduce the drawbacks of current commercial products and their lack of regenerative properties. These dressings have been shown to be formable from several different material platforms both with and without additives known to be beneficial to wound healing. Our technology comprises an in-house developed handheld applicator device, loaded with sealed sterile cartridges of proprietary material formulations which are converted to fibrous substrates through a process known as electrospinning and deposited painlessly onto the patient.

At Crane Biosciences, we enable RNA treatments for incurable diseases. We are based at Imperial College London and backed by Norrsken, InnovateUK, Entrepreneur First, and Creative Destruction Lab (University of Oxford).

At Creo Medical we are dedicated to improving patient outcomes by bringing advanced energy to therapeutic endoscopy. Our integrated electrosurgery unit delivers Bipolar Radiofrequency for precise dissection and resection and Microwave energy for controlled ablation and coagulation. This technology sets a new standard for Endoscopic Submucosal Dissection with our new Speedboat RS2 instrument: the Bipolar Radiofrequency cut allows precise dissection and the microwave coagulation provides controlled haemostasis while the protective hull reduces the risk of muscle damage and the integrated injection needle helps to maintain submucosal lift without instrument changes.

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

We are building a genetic therapy platform to develop curative solutions for peripheral nerve disorders starting with Neurofibromatosis type 1

Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged. Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes. We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets.

Pioneering the next generation of precision medicines to deliver a portfolio of transformative cancer therapies. Dark Blue Therapeutics is an innovative drug discovery biotechnology company based in Oxford, UK. We have assembled a highly experienced team, whose expertise spans the breadth of drug development from discovery to approval. This expertise has been gained over many years in the industry and draws from biotech, large pharmaceutical companies and investment management. Dark Blue leverages ground-breaking cancer biology insights, from Oxford University, to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. With this deep, proprietary understanding of target biology we match our precision medicines to molecularly defined patient populations to develop transformative, durable drugs that address critical unmet patient needs, delivering medicines that transform the outcomes for cancer patients. We work across a variety of biological mechanisms to identify and pursue only cancer targets that have the highest transformative potential.

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects. For further information on the company, please visit www.destinypharma.com

Diabetes currently effects over 537 million adults worldwide, with obesity-driven Type 2 Diabetes accounting for over 90% of cases. Dia Beta Labs build on over 30 years of high-impact research from our founding research group at Ulster University to realise the potential of next-generation therapeutics for metabolic disease. It is our goal to impart significant and much-needed change in the management of the global diabetes/obesity crisis.

DIOSVax is a biotech startup working to revolutionise the way humanity protects itself from infectious disease and emerging pathogens. The company is named after its core technology, DIOSynVax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines), a new system that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.

DJS Antibodies acquired by Abbvie (10/20/22) DJS Antibodies was founded upon a vision of creating the next generation of antibody therapeutics. The company is dedicated to developing novel therapeutics to treat chronic inflammatory diseases through the discovery and development of antibodies.

Dr Falk Pharma UK was established in 2005 to provide the Dr Falk organisation with its own company in the UK and Ireland. Dr Falk Pharma is a family owned business based in Freiburg, Germany developing medicine to treat a wide range of gastrointestinal disorders and hepatobiliary disorders for over 60 years. Guided by the Falk philosophy, Dr Falk UK is dedicated to improving patient outcomes through working alongside healthcare professionals, researchers and patients to develop therapies that work for people not just diseases. Dr Falk also facilitate educational events and support patient societies to promote shared learning. Now for the first time FalkPlus brings everything we do together in one place. Tap in and join the community no matter where you are in the UK by using the Register button above. We look forward to seeing you. Dr Falk Pharma UK's Social Media Policy: https://www.drfalk.co.uk/dr-falk-pharma-uk-social-media-community-guidelines/

Duke Street Bio is focused on exploiting tumour genetic vulnerabilities and harnessing the natural power of the body’s immune system to fight cancer.

Dunad Therapeutics is focusing on the development of next-generation targeted protein degradation therapies. Dunad’s platform enables selective degradation viadirect target modification using tuneable mono-valent small molecules, unlocking new target space and allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.

The world's first non-invasive solution to treat and reverse cataracts. Our scientists have been working to develop a completely novel therapeutic approach to the treatment of cataracts based on the use of light rather than surgery or drugs. Cataracts develop slowly over many years and the gradual changes often go unnoticed at first. LEDINBIO uses light energy with specific wavelengths to reform the proteins in your eye which allows light to pass through allowing you to see clearly and brightly once again.

Elasmogen is a therapeutic biologics company developing multi-functional products for difficult-to-treat diseases. The company has built a product pipeline that exploits the advantages of its proprietary, patent protected soloMER technology including first-in-class drug conjugates (SDC) and bi-specific products for the treatment of autoimmune diseases. Our oncology assets include a pipeline of differentiated soloMER-targeted RadioPharmaceutical Therapies (RPT) for the treatment of solid tumour cancers.

Eleven Therapeutics is a biotechnology company leading the AI revolution in nucleic acid therapeutics. They harness the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process.

EmstoPA is a first in class antibody-based reversal agent to treat bleeding caused by tissue plasminogen activator (tPA - Activase®, Alteplase®). tPA is a “clot buster” used to remove the blood clots that cause stroke, pulmonary embolism, and myocardial infarction. In the developed world, tPA is most frequently used to treat acute ischemic stroke where the rates of subsequent intracranial hemorrhage (ICH) are 5-7% . EmstoPA belongs to a class of drugs called anti-fibrinolytics, and and the current market for antifibrinolytics is estimated to be $1,100m /year. Currently no specific tPA reversal agents are in development.

Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover novel cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing database of Dark Antigens that can address the unmet need for cancer-specific targets that are homogenously expressed and highly prevalent in solid tumors. We are advancing multiple approaches to exploit these Dark Antigen targets, with an internal focus on TCR-directed immunotherapies, and additional therapeutic partnerships with Boehringer Ingelheim and another undisclosed global pharmaceutical company.

To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.

Ennogen is a privately owned British company offering a range of medicines, medical devices, and unlicensed medicines. It was founded in 2011 by CEO John Ruprai.

EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.

Designer Sponge RNAs for Cellular Health Restoration

Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.

Esox Biologics utilises their extensive knowledge of the aquatic microbiome to provide disease prevention solutions that help improve livestock health and welfare.

Essential Pharma is an international specialty pharmaceutical company dedicated to maintaining access to clinically differentiated, niche medicines in small patient populations. Our high-impact portfolio has a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease, and our products treat patients in more than 70 countries. We are proactive in identifying low volume, difficult-to-manufacture therapeutic products, and late-stage clinical development assets that target rare diseases. We specialise in the acquisition of mature, established, branded medicines that are at risk of shortages or discontinuation, working with partners across the globe to ensure their continued manufacture to the highest standards. Essential Pharma comprises innovative and driven people who are passionate about ensuring continued supply of medicines to patients. We are committed to living by our values – Collaborative, Responsible, Trustworthy and Dynamic – and pride ourselves on our inclusive culture, where everyone's voice is valued and respected. We have an unwavering dedication to employee growth and believe in fostering an environment where all individuals can thrive.

Etcembly’s vision is to decode immune repertoires for health and disease. The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally. We are pushing the frontiers to explore the intersection between immunology and machine learning.

A specialist in computational drug discovery with a focus on developing RNA interference (“RNAi”) therapeutics

Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease. Our pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.

Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs. Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics. Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.

eXmoor is a full service Cell & Gene Therapy CDMO with a difference. We are backed by 20 years consultancy experience supporting over 150 organisations accelerate novel therapies from discovery to patients. We provide expert solutions at all stages of the development journey from early process development and scale-up through to GMP manufacture, fill and finish and QP release. We are open, transparent and will work with you at every step to de-risk and streamline your project and maximise the chances of product success.

Getting genetic syntax right. With precise use of genetic grammar in transgenic design, ExpressionEdits unlocks the capacity to make proteins previously beyond reach.

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiates the orotomides from the currently marketed antifungal agents. Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective. Olorofim is in a Phase 2b open-label study focusing on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis and scedosporiosis (including lomentosporiosis). Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA. F2G is headquartered in the UK with subsidiaries in the US and Austria.

Five Alarm Bio is a drug discovery company based in Cambridge, UK focusing on novel approaches to anti-aging, with broad potential therapeutic application. We are researching therapeutics that boost the body's ability to defend against the damage of aging.

Forcefield Therapeutics is a pioneer of best-in-class therapeutics to retain heart function via the protection of cardiomyocytes. Forcefield Tx was founded on the work of Professor Mauro Giacca, an authority in cardiovascular disease and genetic biology and the Heat of the School of Cardiovascular Medicine and Sciences at King’s College London as well as industry experts and investors with a shared purpose to revolutionise treatment following acute myocardial infarction (MI). Forcefield’s unique approach can both retain and protect heart cells, minimising the impact of MI and preventing the cascade of events that may lead to subsequent heart failure. Forcefield Tx is led by a proven team with a record of success from discovery to commercialisation and is backed by a leading FTSE 250 healthcare company, Syncona.

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

Genflow Biosciences plc (LON:GENF) (OTCQB:GENFF) is a UK-based biotech company with R&D facilities in Belgium and a U.S. office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results. Managed by an experienced team with decades of experience in the pharmaceutical and biotechnology sectors, the company is optimistic that development programs will continue at pace in the next 24 months.

We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).

George Medicines is a late-stage drug development company focused on improving the management of non-communicable diseases with innovative, single-pill, fixed-dose combinations of existing medicines. Combining best-in-class molecules from existing medicines in fixed- and low-dose formulations, George Medicines is developing innovative and proprietary treatments that are more efficacious, safer and affordable than currently available treatment options. These single-pill, fixed-dose combinations offer the potential to bring significant improvements in clinical outcomes and therapy adherence in patients with cardiometabolic diseases such as heart disease, hypertension, and diabetes, which remain the leading causes of premature death and disability worldwide. George Medicines is building a strong and diversified pipeline of patented, single-pill, fixed-dose combination therapies in late stage development. Its lead candidate for the initial treatment of high blood pressure, GMRx2, has received clearance from the US Food and Drug Administration (FDA) to enter Phase III development. George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world's leading medical research institutes in non-communicable diseases.

Glen Clova Scientific Ltd (GCS) is developing a new generation of Active Biologics to treat inflammatory conditions. We are an ambitious spinout from the University of Dundee aiming to address the global need to make effective treatments available for millions of patients. Our novel Virus-Like-Particle technology is poised to address inherent limitations of the current blockbuster class of Biologic drugs. Our vision is to make high end biotech pharmaceuticals much more accessible to patients than current blockbusters. #Glenclovascientific #Dundee

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Discovering and developing innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world.

At Harness Therapeutics we have one mission – physiological upregulation of targets that have the promise to provide disease-modifying therapeutics for neurodegenerative diseases. We use a range of mRNA-targeted oligonucleotide-based methodologies to alter the post-transcriptional regulation of protein synthesis and so increase the target protein in a controlled manner. Our focus on neurodegenerative disease is driven by our passion to develop truly disease-modifying therapies for diseases that affect so many people, yet for which there are few if any therapies that can slow or halt the progression of the disease. The ability to effect controlled increases of protein levels is essential in being able to safely drug targets with narrow therapeutic windows, something that existing platforms cannot achieve. This is critical for neurodegenerative disease as there are now a number of targets that have strong genetic validation linked to disease progression but require controlled increases rather than knock-down or over-expression. Our goal is to open up the target space for neurodegenerative disease and be able to advance effective treatment solutions for the tens of thousands of patients and their families who are facing the certainty of irreversible disease progression, loss of quality of life, and ultimately death. Our name reflects our approach, built and refined since our formation in 2020; harnessing the body’s endogenous cellular processes controlling protein synthesis to achieve controlled increases in protein levels in the safest possible manner. We use our deep expertise in RNA biology/bioinformatics and neuro cell biology to probe the intricate regulation of each target and identify multiple upregulation opportunities. Our multi-year experience focussed on physiological upregulation has allowed us to develop bespoke assays and analytical techniques to screen for constructs that drive small increases in protein, which is a key challenge in this space. Our sole focus on neurodegeneration has allowed us to build deep expertise in the biology of neurons and our targets, and the best possible models for disease – critical in being able to de-risk and translate candidates to the clinic. Neurodegenerative disorders are chronic conditions that destroy parts of the nervous system over time, especially the brain. They result in progressive loss of cognitive and motor function and eventually, death. The most common neurodegenerative diseases include Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis (ALS), Motor neuron disease (MND), Huntington’s disease (HD), Spinal muscular atrophy (SMA), and Spinocerebellar ataxia (SCA). It is estimated that more than 50 million people worldwide are affected by neurodegenerative diseases and this number is increasing as overall life expectancy increases. Most of these conditions are much more likely to happen in people over 65, but some conditions like Huntington’s disease and ALS often appear much earlier.

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are more than 10,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Huma's technology has powered over 3,000 hospitals and clinics, with 500+ unique deployments across 70+ countries. The software has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as working with most large pharma companies and CROs. The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, and Saudi FDA Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.

hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

Ikarovec is a UK-based biotech gene therapy company with a focus in ophthalmology. Ikarovec was originally formed as a spin-out from the biotechnology company.

Iksuda Therapeutics is a biotechnology company focussed on the development of a new generation of antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of non-prodrug/prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform.

ILC Therapeutics (ILCT) is a Scottish-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of hybrid interferon drugs. The company is focused on modulating the Innate Immune System through the development of innovative therapies. ILC Therapeutics has raised significant funding to advance its lead interferon drug candidate and has announced its first international collaboration. The company is dedicated to revolutionizing the treatment of various diseases through its cutting-edge research and development efforts.

Immodulon Therapeutics Limited is a private, clinical-stage, immuno-oncology company dedicated to the development of novel, safe and effective treatments for cancer patients.

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company’s lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

Our vision is to provide the world with the next-generation of therapeutics for unmet medical needs and future threats.

Incanthera is a company with a current focus on a range of dermatological applications utilizing its unique formulation and delivery technologies.

We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.

Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, developing vaccines for the treatment of cancer.

IngenOx Therapeutics is a clinical-stage Oxford University spinout developing innovative drugs and vaccines aimed at re-invigorating the immune response against cold tumours.

Inspira Pharmaceuticals is a biotechnology company that specializes in preclinical research for diseases of the respiratory tract.

Intima Bioscience - A clinical stage gene and cell therapy company focused on curative intent in solid tumor cancer

IntraBio Ltd., which is a subsidiary of IntraBio Inc, is a private pharmaceutical company located in Oxford, United Kingdom, focusing on the testing and development of novel and repurposed drugs to treat rare neurodegenerative diseases including lysosomal storage disorders.

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis. Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

iosBio believes that thermally stable, self-administered vaccines in capsule form are the future. Due to its OraPro™ platform, these are inexpensive to produce, developed in weeks and, following regulatory approval, can be distributed by mail. iosBio is using this approach to tackle the global COVID-19 pandemic, developing a capsule-based vaccine that could be easily distributed to millions across the globe. This comes after successfully working on an oral vaccine for the Zika virus. iosBio’s OraPro™ technology means these thermally stable viral vector-based vaccines can be delivered in capsule form to the GI tract. Viral vectors result in vaccines being developed cheaply and quickly, while administration via the gut elicits both mucosal and systemic immunity and allows for repeated administration of the same vector. In contrast, injected viral vector injections only target systemic immunity and can be used just once or twice as immunity to the vector itself is developed. This is made possible by iosBio’s THERM-SB technology. It allows for the storage of vaccines and viruses in powder form at ambient temperatures, eliminating the need for a cold chain to protect vaccines and other biotherapeutics when being delivered and in storage. Adopting this method can redefine the global approach to virus immunity. It will reduce our current reliance on often impractical mass vaccination programmes. These are based on injections that require huge numbers of healthcare professionals and expensive global cold-chains or even a -80⁰C cryo-chain. Through a combination of THERM-SB and OraPro™, iosBio is making its vision for an oral vaccine future a reality.

Isogenica is a bespoke biotech CRO specialised in solving antibody discovery and engineering challenges with small-format antibodies, particularly VHH single-domains. Sometimes known as nanobodies, sdAbs, or heavy-chain single domains, VHHs offer exceptional robustness, flexibility, and manufacturability - , accelerating antibody discovery and development. Their versatility makes them suitable for use in bi-specifics, ADCs, cell and gene therapies, targeted protein degraders, diagnostics and much more. We believe VHHs are the future of medicine - and our synthetic technology gives our VHH libraries the edge in accelerating your drug discovery and development programmes so you can focus on developing the ideas and technologies that could change lives. Offering the largest and most diverse synthetic VHH (nanobody) libraries available on the market, combined with our proprietary CIS display technology, means that VHH discovery with at Isogenica can interrogate up to 1000x more VHH antibody sequences than other display technologies. Our knowledge and experience of VHH, combined with our synthetic libraries’ size and diversity help deliver better antibodies faster, with higher affinity and broader IP coverage. Our in-house experts tailor each project to meet bespoke needs, allowing us to provide industry-disrupting antibody solutions to our partners in around half the time of a traditional animal immunisation campaign. Originally founded near Cambridge, UK over 25 years ago, Isogenica has evolved to become The VHH Company. As an established and trusted antibody partner, our track record of success includes dozens of lead panels including three clinical-stage assets. This bespoke and collaborative approach to antibody discovery extends to how we do business - working flexibly with different partners with uncompromising passion and dedication.

Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we're working at the cutting edge in the new era of ‘digital biology'. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.

We are a clinical stage company developing novel therapeutics inspired by kanna, or Sceletium tortuosum. Kanna is a medicinal succulent traditionally used by the San hunter-gatherers of South Africa.

Kaerus is leveraging advances in human genetics to discover and develop targeted therapeutics for rare genetic syndromes of neurodevelopment.

Keapstone Therapeutics is a single asset biotech developing drugs that target the Nrf2 signalling pathway (KEAP1 inhibitors) for two devastating conditions – Parkinson’s and Motor Neuron Disease (MND) – which together affect more than 130,000 people in the UK. Keapstone was co-founded in February 2017 by the University of Sheffield, Parkinson’s UK and Dr Richard Mead and Prof Pamela Shaw of the Sheffield Institute for Translational Neuroscience (SITraN). The company combines world-leading research from the university with funding and expertise from Parkinson’s UK and consultants and discovery partners with extensive drug development expertise.

Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of genetically modified MSCs.

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Their mission is to accelerate the discovery of next-generation therapeutic antibodies that have been designed for maximum potential. They are headquartered in London and their core technology platform, EVA™, enables the development of novel protein therapeutics.

Laverock was founded around the core Gene Editing induced Gene Silencing Platform – a step-change in RNAi technology. We fundamentally believe it unlocks the development of next-generation therapeutics through its unique and differentiated properties. We are actively developing a pipeline of GEiGS enabled ex vivo cell therapies, as well in vivo therapeutic approaches.

Leucid is progressing novel CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers.

Levicept Ltd is a UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. LEVI-04 is currently in a phase II study in patients with osteoarthritis of the knee.

At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess.

Based at the Babraham Research Campus in Cambridge, LinkGevity is a pioneering drug discovery company founded on ground-breaking research in longevity science. Our goal is to change the paradigm of ageing, paving the way for people to live healthier lives for longer.

Lirum Therapeutics is an innovative biopharmaceutical company focused on the treatment of debilitating diseases.

Locate Bio bring together Programmed Drug Release and Instructive Tissue Scaffolds to develop the next generation of products with significant disruptive potential for musculoskeletal conditions.

LoQus23 Therapeutics is a company that targets DNA mismatch repair pathways to slow neurodegeneration in Huntington's Disease and other triplet repeat disorders. Recognizing the urgent need to find a treatment for patients with triplet repeat expansion diseases, LoQus23 Therapeutics was co-founded in 2019 by David.

Macomics is a biotechnology company that focuses on developing precision medicines to modulate macrophages for the treatment of cancer.

Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch, which is based on a proprietary adhesive developed by its scientists. The Company was founded by Professor David Haddleton and the University of Warwick in 2015 based on their world-leading expertise in bioadhesives and polymer chemistry. The adhesive has a high drug loading capacity, so a smaller quantity of adhesive is needed to deliver a therapeutic dose; the patch can therefore be thinner and more flexible. It also enables excipients, such as permeation enhancers, to be included in the adhesive so the release of the drug from the patch can be tailored to achieve the desired product profile. The adhesive also provides excellent adhesion, even in moist conditions. This means that the patch remains in contact with the skin throughout the dosing period, so the full dose is delivered. There is no leakage of adhesive from the patch so there is no unsightly black ring around its edge and no residue on the skin after removal. Medherant undertakes feasibility studies for other companies to investigate whether their drugs can be formulated for transdermal delivery using the TEPI technology. Medherant welcomes enquires from companies interested in licensing its products for commercialisation or undertaking feasibility studies.

Medicxi is an international investment firm focused on the life sciences sector. It wasestablished in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

MediSieve is a London biotech start-up developing Magnetic Haemofiltration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available for this product in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. Magnetic Haemofiltration has already been shown to rapidly, specifically, and effectively remove IL-6 from human plasma. The technology has completed pre-clinical validation, including animal studies, and is expected to start clinical studies in Q2 2022. MediSieve has raised £4M in equity funding and over £4M in non-dilutive grants. Seeking a further £8M at Series A to support pivotal clinical trials and regulatory approvals. EIS eligible. The company has been featured in numerous online and print media articles, including the Sunday Telegraph, Daily Mail, and Wired Magazine, and been winner or finalist in several start-up competitions such as Pitch@Palace, MassChallenge, OBN Awards, TCT Magazine Awards and CMS Healthcare Startup of the Year. Recently, our founder George Frodsham was awarded BBSRC Innovator of the Year and MIT Innovators Under 35.

Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused and capital efficient manner. Our journey began back in March 2015 fuelled by the desire to champion high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired three product candidates from Novartis in 2015 and one from AstraZeneca in 2017. Merging with OncoMed in 2019 strengthened our foundation, broadening our reach and adding cutting-edge oncology programs to our pipeline. The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options. Mereo’s agile approach is enabling us to move rigorously but quickly through trial programs. We have taken two therapies from in-licensing to pharma through to Phase 3 studies in under 5 years. Our portfolio covers potential therapies addressing critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and two oncology product candidates. Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across pharma and biotech. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We know what it takes to navigate reimbursement, which can be complex and have the expertise to drive excellence. Follow our updates on this extraordinary journey as we continue to collaborate with our stakeholders to forge new ways of doing things in rare disease.

Mesenbio is a preclinical biopharmaceutical business based at the University of York. Its Cell Line Extracellular Vesicle therapeutic is aimed at delivering next-generation medicine to patients.

Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career.

MetalloBio are developing two novel antimicrobial leads to combat multi-drug resistant Gram-negative bacteria.

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers

Micrographia Bio (MGB) has developed a new approach which uses spatial proteomics for stunningly sensitive and high-throughput assessment of the true molecular effects of drug candidates.

An R&D company focused on delivering innovative oncology and rare disease products to patients. Midatech has three platform technologies that are focused on improving bio-distribution and bio-delivery of medications in different ways – either via sustained delivery, targeted delivery, or direct delivery. These are: microspheres, saccaride nanoparticles, and gold nanoparticles.

We are pioneering the use of semiconductor technology for next-generation neural implants. Our mission is to provide the best possible outcomes for patients with neurological conditions by delivering the highest performance with the least invasive surgery. Our team brings together world-class experts in neuroscience, microtechnology, and implantable neural interfaces — augmented with medtech industry pedigree and clinical experience.

Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes of pH, seawater, or high concentrations of organic solvents. In addition, MIPs have a very long shelf life at room temperature which makes them ideal when the cold chain cannot be guaranteed. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. Using our proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP typically within 4-6 weeks of receiving the target.

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

Monument Therapeutics is an independent UK based biotechnology company formed as a spin-out from Cambridge Cognition. The company is focused on bringing precision medicine to neuroscience drug development, with a pipeline of proprietary biomarkers that allows precise selection of patients most likely to benefit from treatment. Monument Therapeutics is de-risking development by repurposing drugs with a favorable safety profile and proven mechanisms.

Morvus Technology Limited is a privately owned pharmaceutical company specialising in the discovery and development of novel drugs and diagnostics for the oncology sector. It has offices near Brecon, Wales. Morvus was formed in 2004 after the founders’ previous company, Enact Pharma plc, was acquired. Initially based on the Porton Down Science Park, near Salisbury, in 2007 the company relocated, with considerable assistance from the Welsh Government, to its present site. The company has a diverse portfolio of oncology therapeutics and diagnostics and its lead drug is a potent anti-tumour agent that displays minimal toxicity to normal tissues and is rendered harmless in the circulation. Morvus is developing this drug as a potential treatment for lung cancer using an inhalation route to deliver the drug to tumour sites. The drug is also being assessed as a potential agent to treat some skin cancers.

Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.

Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East. Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do. We encourage our people to think differently and our inclusive culture of continuous learning and collaboration make Mundipharma a great place to work. For more information visit www.mundipharma.com See our community guidelines: mundipharma.com/social-media-community-guidelines

Nanogenics Ltd is a research-based biotechnology company, engages in the development of artificial viruses to deliver gene therapy.

NanoSyrinx is a cutting-edge synthetic biology company creating the next generation of targeted drug delivery systems to address challenges in the biologic delivery sector.

Nanovery is a biotechnology company founded in 2018 and based in Newcastle Helix, UK. The company specializes in nucleic acid nanorobotics, focusing on developing liquid nanorobot technology to advance nucleic acid research, particularly in RNA therapeutic analysis and biomarker quantification. Nanovery operates in the biotechnology sector, emphasizing research and development. The company's main offering is a proprietary platform that utilizes DNA nanorobotic sensors to quantify nucleic acid sequences in liquid samples. This platform simplifies the testing process by adding nanorobots to samples and measuring fluorescence to determine nucleic acid concentrations. Nanovery's technology supports RNA therapeutic development, biomarker analysis, and disease diagnostics, including early-stage detection. The integration of AI enhances data analysis and scalability, making the technology suitable for complex media. Nanovery has raised a total of $2.92 million in funding, with notable investors including Northstar Ventures and Innovate UK. The company aims to streamline testing protocols in biotech research, focusing on speed, cost-efficiency, and accuracy.

NeoPhore is a UK-based company founded in 2017, developing novel cancer therapies based on DNA-repair technology. The company targets the dynamics of cancer neoantigen evolution and aims to create effective medicines that will become a key part of the next-generation of cancer treatment.

NeRRe Therapeutics is developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders. Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy and there are no approved treatments. Idiopathic pulmonary fibrosis has been designated an orphan disease in both Europe and the USA

‘Neuro-Bio has discovered a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE. T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of neurodegeneration. This new distinct mechanism is being exploited by Neuro-Bio to discover first-in-class drugs to treat Alzheimer's disease and to develop a biomarker as a companion diagnostic'.

Neurochase was founded by a team of physician-scientists led by Professor Steven Gill in response to the growing need for CED consultancy services in the life science industry. Professor Gill is an Honorary Professor of Neurosurgery at the University of Bristol. He is a world leading expert in CED and has spent the past 20 years developing technology to facilitate highly accurate and safe targeting of deep brain structures using software and surgical robots. To learn more about Professor Gill, watch the following video interview where he discusses his clinical experience of intermittently delivering chemotherapy directly to paediatric brainstem tumours using his novel implantable neurosurgical device. Our Science: Convection Enhanced Delivery (CED) provides a method of achieving effective doses of therapeutics homogenously in targeted brain volumes that cannot be achieved safely with systemic or CSF delivery. Therapies are infused into the brain via micro-catheters and can be distributed in tightly controlled doses throughout the required treatment volume. The blood brain barrier now acts to retain the therapy in the brain targets thereby minimising systemic and off-target exposure. We believe that safe and scalable delivery of novel therapeutics by CED is achievable and will transform human health by unlocking treatments to previously untreatable neurological disorders.

Based in Belfast, Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world's greatest health challenges! Modius is the first product from Neurovalens which successfully launched in August 2017 on Indiegogo. Modius was designed to help improve the lives of people who struggle with their weight by using neuro-technology to help make weight loss easier.

NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours. Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms.

NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond

NRG Therapeutics is passionate about bringing new medicines and hope to the growing number of people worldwide living with debilitating neurodegenerative diseases. The company is an innovative neuroscience company targeting mitochondrial dysfunction for the treatment of neurodegenerative diseases such as Parkinson's and ALS. NRG Therapeutics has been awarded a $500K grant from The Michael J. Fox Foundation to progress its Parkinson's program and has also announced a £16 million Series A to advance its mitochondrial therapeutics for Parkinson's and ALS.

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising our proprietary ProTide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

OKYO Pharma is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of inflammatory eye diseases and chronic pain. The company's main focus is the clinical development of OK-101 to treat dry eye disease (DED).

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Science Enterprises.

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. For more information, please visit www.orchard-tx.com.

"Living Organs For Life"​ Transforming transplantation with the OrganOx metra®. A transportable, automated ex vivo liver perfusion device. The core technology employed by the OrganOx metra® has been in development for over 15 years. During this time both of the founders (Professor Peter Friend and Professor Constantin Coussios) have driven the development of organ preservation and maintenance, formerly at the University of Cambridge and latterly at the University of Oxford. OrganOx Limited was founded in April 2008 as a spin-out from the University of Oxford. Conventional cold preservation involves storage of the liver at 4˚C, using a non-physiological perfusion solution that aims to minimise liver decay. By contrast, warm preservation seeks to re-create an environment that mimics the human body by continuously perfusing at physiological pressures and flows with oxygen-carrying red cells at 37˚C and providing nutrition. The liver is therefore functional during the preservation period, producing bile, metabolizing glucose and maintaining a physiological pH. This enables objective assessment of organ performance prior to transplant, extended preservation times, and the potential use of organs that are presently being discarded.

Orion Pharma (UK) Ltd. is a wholly owned subsidiary of Orion Corporation, pharmaceutical company based in Finland. Our principal role is to represent Orion's pharmaceutical products in the UK across a range of therapy areas including Respiratory, Women’s Health and Neurological Disorders. In the spirit of the values which are common to all units and employees of the Group, we endeavour to provide innovative medicinal treatments and best quality service to patients, healthcare professionals and the community in the UK, the region we operationally cover. We are continuously developing new drugs and treatment methods. The core therapy areas of our pharmaceutical R&D are oncology and pain. We collaborate closely with healthcare professionals and leading global research institutions and pharmaceutical companies. www.orionpharma.co.uk July 2023/CORP-233(3)

OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds. The company is headquartered in the University City Science Center in downtown Philadelphia and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts, UK. Ossianix was founded by Frank S Walsh, Corey Goodman and Lynn Rutkowski who have had distinguished careers in academia, Pharma and Biotech and bring a wealth of experience to the problem of delivering the next generation of Biologics products. The company started operations in 2012 with funding from Lundbeck Pharmaceuticals, BioAdvance and the ALS Association. Current programs focus on neurodegereration, neurooncology, ALS, pain and botulism.

Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.

Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.

Owlstone Medical is developing a breathalyzer for disease. With a goal of finding ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health, and other conditions. Our mission is to save 100,000 lives and $1.5B in healthcare costs by advancing early detection and precision medicine. Breath Biopsy® aims to develop a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA® Breath Sampler ensures the reliable collection of breath samples. The volatile organic compounds (VOCs) present in breath are analyzed using state-of-the-art chemical analysis technologies. Our aim is to develop tools, potentially based on our proven microchip chemical sensor technology (FAIMS), to detect validated biomarkers of disease. The Breath Biopsy platform provides biomarker discovery and validation capabilities to support the development of applications in precision medicine for a wide range of other medical conditions. Highly sensitive and selective, our platform allows for early diagnosis when treatments are more effective and more lives can be saved. Owlstone Medical is involved in studies related to major and rapidly growing health concerns including lung cancer, asthma and liver disease. We are also participants in extensive partnerships focusing on multiple cancer types, pulmonary hypertension, mesothelioma, workplace exposures and much more. Our Breath Biopsy Products and Services are available to academic, clinical, and pharma research partners who want to develop breath-based diagnostics for their own applications. Our products and services are for research use only. Not for use in diagnostic procedures.

Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).

Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates with highly innovative chemical scaffolds and modes of action.

Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a bio-pharma company that was spun out from the University of Oxford’s Department of Oncology and is utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for therapeutic vaccines and diagnostics in cancer and infectious diseases. The technology uses the novel, proprietary platform of ROPs to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other immune oncology (IO) agents. The company has extensive contacts and collaborations in China through Changzhou Bioscience Group (CBIG) that is using the ROP platform for diagnostics in both cancer and in infectious diseases. OVM is developing two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines will be tested as single agents and in combination with IO agents. OVM secured Series A investment from Cancer ROP, a leading South Korean healthcare institution, listed in KOSDAQ, and from existing shareholders in China in 2018. The company is currently seeking Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and also in combination.

“One treatment a year. Life changing.” Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.

Pathios Therapeutics is a clinical-stage oncology and immunology company that targets the acid-sensing GPCR, GPR65. The company is focused on the development of first-in-class therapies for cancer.

Perspectum's imaging solutions are safe, fast, and can offer more comprehensive diagnostics. We help doctors understand complex data and help deliver precision care to more patients. We believe the voice of the patient matters and that each case is unique. Our goal is to enable health care providers to tailor precision medicine to the needs of the individual.

Welcome to the Phagenesis LinkedIn page!  At Phagenesis, we are dedicated to transforming the way dysphagia is treated. Dysphagia, or difficulty swallowing, can be a debilitating condition that affects millions of people worldwide. We believe that everyone deserves the ability to enjoy their meals and live their lives to the fullest, which is why we have developed the Phagenyx - a revolutionary product that uses Pharyngeal Electrical Stimulation (PES) to treat dysphagia.  The Phagenyx is a simple, non-invasive device that stimulates the nerves in the pharynx, helping patients regain control of their swallowing function. Our product has been rigorously tested in clinical trials and has been shown to significantly improve swallowing ability in patients with dysphagia.  As a company, we are committed to advancing the field of dysphagia care through innovative technology and evidence-based practices. We work closely with healthcare providers and patients to ensure that our product meets the highest standards of safety and efficacy.  We are proud to be changing the paradigm of dysphagia care, and we invite you to join us in our mission to improve the lives of millions of people around the world. Follow our page to stay up-to-date on the latest news and developments in dysphagia care, and to learn more about the Phagenyx and how it is helping patients overcome dysphagia.

Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).

At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”.

PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using this core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.

Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details.

Pneumagen is a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, as an intranasal drug for the prophylaxis of a wide range of viral respiratory tract infections (RTIs). Neumifil is a novel, engineered multivalent Carbohydrate Binding Module (mCBM), which is being developed for the prevention and treatment of Influenza Virus, Respiratory Syncytial Virus, Human Rhinovirus, and Coronavirus infections including SARS-CoV-2 virus. Neumifil acts by binding directly to sialic aid on host cells and preventing the entry of the viral pathogens into the host. Neumifil was generated using Pneumagen’s proprietary GlycoTarge™ technology that identifies novel mCBMs for further development. In addition to Neumifil, Pneumagen is harnessing its GlycoTarge™ platform to develop a pipeline of additional therapies targeting other infectious diseases. Pneumagen was established in 2016 as a spin-out from the University of St Andrews in Scotland giving Pneumagen access to world-class scientific expertise and capabilities in viral RTI’s specifically related to glycobiology.

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

Procarta Biosystems Ltdaims to revolutionise the treatment of serious and life-threatening infection through the development of innovative new oligonucleotide-based antimicrobials.

Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.

ProteinLogic has developed ImmiPrint®, a novel diagnostic technology platform, based on the detection of non-obvious diagnostic patterns in soluble immune proteins in the blood and other body fluids through machine learning.

Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.

An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.

Rayner manufactured the world's first IOL in 1949, and has remained at the forefront of innovation for over 70 years, focused on providing you and your patients with the best IOLs and ophthalmic solutions - always driven by science to improve patient outcomes and safety. Rayner is the only manufacturer of IOLs in the UK, with its state-of-the-art manufacturing plant and Global Headquarters on the South Coast of England. Rayner is a fast-paced and growing business with 500+ employees worldwide.

Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases Our team of scientists are based at our labs at Alderley Park, Cheshire, the UK's largest single site life science campus. The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience. Redx's lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for idiopathic pulmonary fibrosis and commenced a Phase 2 clinical trial in Q4 2022. Redx's second ROCK inhibitor candidate, RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, commenced a Phase 1 clinical trial in Q1 2024. The Company's lead oncology product candidate, the Porcupine inhibitor, zamaporvint (RXC004), commenced a Phase 2 programme in November 2021. The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. Read more about our company at https://www.redxpharma.com/about-us/ If you're interested in joining us, please visit https://www.redxpharma.com to see what job vacancies we currently have.

Polypeptides from Colostrum

We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.

We are a global, clinical stage pharmaceutical company with a mission to develop and commercialise clinically meaningful, novel therapeutics that will bring life-enhancing benefits to children across the world. Our first development program focuses on Hu14.18, a humanised anti-GD2 monoclonal antibody, licensed from St. Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. A novel key Phase II trial incorporated the addition of Hu14.18 antibody to standard induction chemotherapy and demonstrated outstanding outcomes in patients with newly diagnosed high-risk neuroblastoma, with a 3-year event-free (EFS) and overall survival (OS) of 73.7% and 86.0% respectively. Renaissance Pharma Ltd is led by an Executive Team with extensive experience in the development, approval and commercialisation of oncology and rare disease products. We invite industry manufacturers, formulators, researchers and investors to collaborate with us. Together we can build new partnerships to improve patients' lives. To discuss partnership opportunities, please contact info@renaissancepharma.co.uk We invite industry manufacturers, formulators, researchers & investors to collaborate with us. Together we can build new partnerships to improve patients' lives.

Our focus at ReNeuron is on our CustomEx exosome technology platform, producing exosomes with unique tissue targeting tropisms to deliver a payload of choice to a preferred cell type. Our mission is to partner and develop novel exosome therapeutics for diseases with significant unmet needs.

Resolution Therapeutics is a biotechnology company developing macrophage cell therapy to treat inflammatory organ disease. The company was founded following a productive collaboration between Edinburgh’s Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited. The company is based in the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, and is backed by Syncona. Our initial focus is in chronic liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, only supportive therapies are currently available. For patients with end-stage liver disease (cirrhosis) the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors. At Resolution Therapeutics, we are developing a macrophage cell therapy product to treat patients at risk of liver decompensation, thus helping them avoid the need for a liver transplant.

Re-Vana Therapeutics is a venture-backed, pioneering therapeutics and ocular drug delivery company developing innovative sustained-release biologics to treat serious retinal diseases. The company’s proprietary photo-crosslinked, biodegradable platform technologies, EyeLief®, EyeLief SD™ and OcuLief®, enable custom delivery of a wide range of therapeutic molecules. Numerous platform capabilities create a therapeutic continuum to expand treatment opportunities through both internal development and external, strategic collaborations. Re-Vana envisions a new industry standard for sustained delivery of biologics to the retina, creating transformative and differentiated treatments for physicians and significantly reducing patient treatment burden.

Rinri Therapeutics is a private biotechnology company developing first-in-class cell therapies to restore hearing. Hearing loss affects 350m people in the world; 90% caused by sensorineural hearing loss (SNHL). There are currently no disease-modifying therapeutics for SNHL patients. Rinri's pioneering technology seeks to reverse SNHL through the regeneration of the damaged sensory cells in the inner ear, the cochlea. Rinri is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield.

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics’ portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of: 1. Midkine antibodies with significant in vivo efficacy and toxicology studies; 2. Midkine RNA therapeutics with novel anti-cancer gene editing action; 3. MK cell therapy with direct and NK-mediated anti-cancer action; and 4. siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

RQ Biotechnology is making instant immunity a reality for vulnerable people. As the leading passive immunization discovery company, we partner with pharmaceutical companies to develop our antibodies into protect against infectious diseases where vaccines cannot. RQ Bio is dedicated to developing medicines based on potent broad-spectrum mAbs to provide instant and long-lasting protection for vulnerable people at risk of severe disease or death from current and future viral infections.

Built for precision, designed for patients. Sania [sah-nee-ah] is a London based biotech company building therapeutics that transform the lives of people with diseases of dysfunctional neural circuits.

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells. At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.

Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high throughput and high accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes the norm.

Sireau Labs is a new biotech based in Cambridge, UK, that is using mRNA technology to develop ground-breaking treatments for rare genetic diseases. Sireau Labs is engineering solutions for rare diseases with science that is at the forefront of precision medicine. We are in a daily race to save lives stolen or impacted by rare disease.

We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and are maximizing the potential of our technology through research partnerships. Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, we have fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.

Develop safe and effective drug delivery systems for cell andgene therapeutics.

SkinBioTherapeutics is a life science company focused on skin health. SkinBioTherapeutics is targeting five specific healthcare sectors: Cosmetic, Food Supplements, Medical Devices, Hospital and Domestic Surface Hygiene and Pharmaceuticals.

Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care. SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life. Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation. After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds. For more information, you can find our peer-reviewed publications here: Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805 Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079 The importance of our innovative technology has been widely recognised: - Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024 - Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024 - EIC Accelerator Grant (European Innovation Council), 2023 - Life Sciences Innovator (UK Department for Trade and Business), 2023 - EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022 - Winner 2019 URGO Mentorship Programme. Visit us at www.solascure.com

Spirea Limited is a Cambridge-based company created to advance a new generation of antibody-targeted cancer treatments with significantly better efficacy and safety profiles. Spirea will use its innovative technology to enable a pipeline of superior and differentiated antibody drug conjugates for the treatment of a range of solid tumours.

SPOREGEN LIMITED is a biotechnology company based at The London BioScience Innovation Centre (LBIC) in London. SPOREGEN is focused on four areas. 1. Clostridium difficile: we have developed a unique prophylactic and therapeutic approach for C. difficile infection. 2. Probiotics: we identify and develop Bacillus, heat stable, spore probiotic formulations. This includes progression to GRAS status and a number of these have now been licenced including HU58 and HU36. 3. Prophylactic approaches to COVID-19 including SPOR-COV, a unique mucosal immune modulator, and SPORCOVAX, a mucosal vaccine. 4. Contracts: focusing primarily on in vivo evaluations of C. difficile interventions.

SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year.

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak.

SynaptixBio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases.    SynaptixBio's mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. Using a breadth of platforms including antisense oligonucleotide (ASO)-based technology, we can silence the expression of the toxic gene to reverse disease progression. This approach will create life saving treatments for severe genetic diseases that affect the central nervous system.

SyntheticGestalt is an AI startup focused on the life sciences sector, particularly in drug and enzyme discovery. Founded in 2018, the company operates from dual headquarters in London and Tokyo. It utilizes advanced machine learning models to enhance the design, discovery, and analysis of both small and large molecules. The company offers services in drug and enzyme discovery, collaborating with prestigious universities in the UK and Japan. This partnership emphasizes its commitment to scientific research and development in biotechnology. SyntheticGestalt has a diverse international team with expertise in entrepreneurship, pharmaceuticals, consulting, and AI, fostering a supportive work environment that encourages professional growth. With a small team of 11 to 50 employees, SyntheticGestalt is a private limited company incorporated in the UK. Its operations reflect a strong dedication to innovation in the life sciences, supported by grants and collaborations with academic institutions.

Talisman Therapeutics is a human stem cell drug discovery company, based in Cambridge, UK. We are committed to revolutionising the discovery of treatments for Alzheimer’s disease (AD). Our novel human stem cell models of AD provide a transformative platform for rapid and more therapeutically relevant compound identification, thereby offering the potential to significantly accelerate drug discovery and, more importantly, de-risk subsequent development.

A new approach to halting the spread of tau pathology and destruction of nerve cells in the brain Precision immunotherapy for the treatment of tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP)

TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.

T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune & inflammatory conditions. Yet challenges in the identification of therapeutically relevant targets and TCRs has limited the application of such therapies. Our goals: - Develop next generation TCR therapies for treatment of cancer and autoimmune disease - Innovate to make TCR therapies widely available to patients About T-Cypher - Founded in 2021 based on exclusive technology licenses from University of Oxford, and with Oxford Science Enterprises as the major shareholder - Proprietary disease target and TCR discovery platform - Expanding TCR-bank against novel, differentiated targets - Differentiated approach to multiplexing TCRs in therapeutic T-cells - Diverse team with experienced leadership from prominent companies covering cell therapy, gene engineering, immune oncology, autoimmune disease and computational biology

Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately 2 billion people globally. BRIMOCHOL PF has completed its first Phase 3 pivotal trial (BRIO-I) and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and UCL Technology Fund.

Theolytics is a biotechnology company working to transform innovative therapies that represent the promise of lasting cures. The company harnesses viruses to combat cancer and is focused on developing next-generation oncolytic viral therapies.

TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf's strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company's clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos' neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

ThirtyFiveBio is an early-stage drug discovery company that was established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of GPR35. We are currently engaged in a fully enabled drug discovery program to identify novel small-molecule modulators of GPR35

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®'​) technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care. In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.'​, rebranded 'TRX BioSurgery'​ in February 2018. January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany. In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

Tiziana Life Sciences is a dual-listed* (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer related to the liver. Our clinical pipeline includes drug assets for Crohn's Disease, COVID-19 and Progressive Multiple Sclerosis and Hepatocellular Carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience. *Note: Our market cap for TLSA is likely not accurate because its shares are listed on both the London Stock Exchange and the NASDAQ.

We are developing cancer treatments that specifically target the cancer stem cell population in tumors. Targeting these cells will prevent relapse and disease progression leading to long-term patient benefit.

Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by our diagnostic tests to respond.

TRIMTECH has a growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs and TRIMGLUEs. The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.

Trio Medicines Ltd (Trio) is a small pharmaceutical company founded in 2005, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO. Here, we focus on developing treatments for rare and unmet medical needs with the aim of improving the health and quality of life of patients around the world. Here at Trio, we are currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).

Trogenix unites cutting-edge technologies in genomics, oncology, immunotherapy, and gene therapy to create a revolutionary therapeutic approach through its Odysseus platform. Using proven AAV vectors, our proprietary Synthetic Super-Enhancers (SSEs) are delivered directly to tumour cells without detection. Our SSEs enable unprecedented precision in gene control, effectively revealing cancer to the body's immune system and killing tumour cells. For any cells escaping Trogenix's technology, our 'Trojan horse' reawakens the immune system, countering recurrence and offering potentially curative 'one-and-done' treatments for aggressive tumours. With our lead asset showing curative potential in preclinical glioblastoma studies, we're poised to transform treatment paradigms across multiple cancer types and explore applications beyond oncology, such as regenerative medicine.

TRX's technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer, CNS and respiratory diseases and diseases of the immune system using a clinically and commercially proven approach.

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.

TYG oncology is a biotech company that offers novel cancer immunotherapies based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodulation) technology platform. Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific and controlled immune response against cancer.

VacV Biotherapeutics is a cancer immunotherapy company developing innovative viral-based therapies for cancers. Launched in 2022 by cancer immunotherapy pioneers Professor Yaohe Wang, Professor Nicholas Lemoine, Dr. Louisa Chard Dunmall and Dr. Peng Liu, VacV employs a unique approach to immunotherapy based on the Vaccinia virus to stimulate a patient's immune system to fight cancer while simultaneously destroying cancer cells. This approach offers many advantages over existing immunotherapies, including minimized toxicity, higher specificity and efficacy, allowing for efficient systemic delivery of an immunotherapy for the first time.

VaxEquity is a biotechnology company amplifying the impact of RNA vaccines and therapeutics, through using its next generation self-amplifying RNA (saRNA) platform. The Company uses saRNA to provide greatly enhanced protein expression, combining better tolerability with slower release and thermostability. VaxEquity is pioneering a next generation approach by modifying its saRNA to modulate the immune response and thereby overcoming current limitations. The flexibility of the Company’s platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. VaxEquity was founded in 2020 by Professor Robin Shattock, the Head of Immunology of Infection at Imperial College London and is led by a world class team who are pioneers in the field of RNA.

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.

Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. We are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (COPD) and cystic fibrosis (CF), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. We are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. In addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA and on the London Stock Exchange in the United Kingdom under the ticker symbol VRP.L. We are headquartered in London and have offices in the United States.

Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.

Viramal is a Specialty Pharmaceutical Company developing a portfolio of therapies in the fields of male & female sexual health focussing on the utilisation and application of sex steroid hormones. Viramal’s patent protected technology platform facilitates superior drug delivery both transdermally and to sensitive female reproductive areas with an outstanding safety profile. Similar to cosmetic creams, Viramal’s products have excellent patient acceptability, and unlike competitors does not require alcohol for API solubility or absorption enhancement. All of the Company’s products benefit from the avoidance of the First Hepatic Pass, and the safety/ metabolite concerns that result other marketed products, particularly in Menopausal Hormone Therapy. The portfolio is made up of products in the following area’s: 1. Sex Steroid Hormone Deficiencies * Testosterone Replacement for Men * Menopausal Hormone Therapy 2. Reproductive & Fertility * Fertility Support * Endometriosis & Fibromyomas – treating symptoms and enabling fertility within women of reproductive age 3. Contraception & General Sexual Health * Safer and more patient-acceptable daily & emergency contraceptives * Gynaecological health Viramal’s lead product, TestoCream, is expected to be filed for a New Drug Application to the FDA in the US in 2017/18. TestoCream is a testosterone replacement therapy, similar to a cosmetic cream, applied to the skin. Unlike competing products, TestoCream is neither messy nor watery, requiring a smaller area for application, and it is also quick drying. Testosterone is only soluble in alcohol, with competing products having an alcohol content of around 70% or more. TestoCream offers a far safer alternative, having less than 3.5% alcohol, reducing the risk of skin irritation.

WaveBreak (www.WaveBreakTx.com) is a biopharmaceutical company focused transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Alzheimer’s disease, and ALS. WaveBreak was previously Wren Therapeutics.

Xgenera is dedicated to transforming cancer diagnosis through their groundbreaking multi-cancer early detection (MCED) test. With a mission to save lives by identifying cancer at its earliest stages, Xgenera leverages cutting-edge technology and advanced algorithms to detect a wide range of cancers with exceptional accuracy. By detecting cancer earlier, when treatment options are most effective, Xgenera aims to improve patient outcomes and ultimately reduce the global burden of cancer. Backed by data from large patient cohorts and ongoing research, Xgenera's MCED test holds the potential to revolutionise cancer diagnosis around the world. With a commitment to empowering individuals and healthcare providers with timely, actionable information, Xgenera is at the forefront of the fight against cancer, paving the way for a future where early detection saves lives.

Yellowstone aims to unlock a new class of therapeutically targetable frequently expressed antigens with potential to significantly transform patient lives. Spun out of the University of Oxford, Yellowstone is built around the pioneering research of Professor Paresh Vyas, a world-renowned scientific academic, key opinion leader and practising clinician with a specialist focus on acute myeloid leukaemia (AML). The Company is headquartered in Oxford, UK, with backing from a leading FTSE 250 healthcare company, Syncona.